ATE448799T1 - Folatrezeptor gerichtete bildgebende konjugate - Google Patents
Folatrezeptor gerichtete bildgebende konjugateInfo
- Publication number
- ATE448799T1 ATE448799T1 AT03733967T AT03733967T ATE448799T1 AT E448799 T1 ATE448799 T1 AT E448799T1 AT 03733967 T AT03733967 T AT 03733967T AT 03733967 T AT03733967 T AT 03733967T AT E448799 T1 ATE448799 T1 AT E448799T1
- Authority
- AT
- Austria
- Prior art keywords
- folate receptor
- targeted imaging
- receptor targeted
- imaging conjugates
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37857102P | 2002-05-06 | 2002-05-06 | |
PCT/US2003/014379 WO2003092742A1 (en) | 2002-05-06 | 2003-05-06 | Vitamin-targeted imaging agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE448799T1 true ATE448799T1 (de) | 2009-12-15 |
Family
ID=29401611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03733967T ATE448799T1 (de) | 2002-05-06 | 2003-05-06 | Folatrezeptor gerichtete bildgebende konjugate |
Country Status (19)
Country | Link |
---|---|
US (5) | US7128893B2 (de) |
EP (4) | EP2258401B1 (de) |
JP (1) | JP4801348B2 (de) |
KR (1) | KR100978418B1 (de) |
CN (2) | CN100528241C (de) |
AT (1) | ATE448799T1 (de) |
AU (1) | AU2003239383C1 (de) |
CA (1) | CA2484345C (de) |
CY (1) | CY1114733T1 (de) |
DE (1) | DE60330135D1 (de) |
DK (3) | DK2260875T3 (de) |
ES (4) | ES2500922T3 (de) |
HK (1) | HK1141440A1 (de) |
IL (1) | IL164811A (de) |
NZ (1) | NZ536467A (de) |
PT (2) | PT2151250E (de) |
SI (2) | SI2151250T1 (de) |
WO (1) | WO2003092742A1 (de) |
ZA (1) | ZA200408664B (de) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60231868D1 (de) | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
EP1390077B1 (de) | 2001-05-02 | 2014-07-16 | Purdue Research Foundation | Behandlung und diagnose vom makrophagen-vermittelter erkrankung |
US8043603B2 (en) * | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
EP2258401B1 (de) * | 2002-05-06 | 2014-07-09 | Endocyte, Inc. | Folatrezeptor gerichtete bildgebende Konjugate |
AU2003243226A1 (en) * | 2002-05-15 | 2003-12-02 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
EP2529758A3 (de) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate |
JP2007526238A (ja) * | 2003-05-06 | 2007-09-13 | パーデュー・リサーチ・ファウンデーション | マクロファージまたは葉酸受容体を標的とする狼瘡治療法 |
WO2004110250A2 (en) | 2003-05-30 | 2004-12-23 | Purdue Research Foundation | Diagnostic method for atherosclerosis |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
CA2587779A1 (en) * | 2004-11-10 | 2007-01-18 | University Of South Florida | Platinum complexes for targeted drug delivery |
CN101128152A (zh) * | 2004-12-23 | 2008-02-20 | 普渡研究基金会 | 发射正电子段层成像方法 |
US8044200B2 (en) * | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
JP5175723B2 (ja) * | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
EP2382995A3 (de) | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligandenkonjugate von Vincaalkaloiden, Analoga und Derivaten |
CN103893779A (zh) | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
WO2007038346A2 (en) | 2005-09-23 | 2007-04-05 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
CA2668197A1 (en) * | 2006-11-03 | 2008-05-15 | Philip S. Low | Ex vivo flow cytometry method and device |
WO2008098112A2 (en) * | 2007-02-07 | 2008-08-14 | Purdue Research Foundation | Positron emission tomography imaging method |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
EP2604284A1 (de) * | 2007-02-16 | 2013-06-19 | KTB Tumorforschungsgesellschaft mbH | Rezeptor- und antigengerichtete Prodrug |
CA2680535C (en) | 2007-03-14 | 2016-09-20 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
EP2146944B1 (de) | 2007-04-11 | 2014-01-22 | Merck & Cie | Verfahren zur herstellung von 18f-markierten folaten |
CA2670385C (en) * | 2007-04-11 | 2016-01-12 | Merck Eprova Ag | Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy |
EP2164525A2 (de) * | 2007-05-25 | 2010-03-24 | Purdue Research Foundation | Verfahren zur darstellung von lokalisierten infektionen |
WO2009002993A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
AU2008316835B2 (en) | 2007-10-25 | 2015-07-16 | Endocyte, Inc. | Tubulysins and processes for preparing |
EP2222328A4 (de) * | 2007-11-15 | 2013-06-05 | Endocyte Inc | Verfahren zur verabreichung von konjugaten |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
WO2010083104A2 (en) | 2009-01-13 | 2010-07-22 | Emory University | Conjugates of noscapine and folic acid and their use in treating cancer |
US8975389B2 (en) | 2009-03-02 | 2015-03-10 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
EP2403412A4 (de) * | 2009-03-05 | 2013-08-07 | Purdue Research Foundation | Verfahren zur frühen bildgebung von atherosklerose |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
PL2556171T3 (pl) | 2010-04-05 | 2016-04-29 | Prognosys Biosciences Inc | Oznaczenia biologiczne kodowane przestrzennie |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
KR20140026396A (ko) | 2011-03-08 | 2014-03-05 | 어섹스 팔마큐티칼스 인코포레이티드 | 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템 |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
KR102036199B1 (ko) | 2011-08-17 | 2019-10-24 | 메르크 앤드 씨에 | 알부민-결합 개체들의 폴레이트 공액체들 |
EP2800586A1 (de) | 2012-01-03 | 2014-11-12 | Invictus Oncology Pvt. Ltd. | Auf liganden gerichtete moleküle und verfahren dafür |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US9629918B2 (en) | 2012-02-29 | 2017-04-25 | Purdue Research Foundation | Folate receptor alpha binding ligands |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US20150174273A1 (en) * | 2012-07-25 | 2015-06-25 | Emory University | Imaging and therapeutic methods for treating parathyroid tumors |
WO2014062697A2 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
KR101551232B1 (ko) | 2012-10-26 | 2015-09-10 | 한국원자력연구원 | N3s1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물 |
KR102499944B1 (ko) | 2012-11-15 | 2023-02-14 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
WO2014150943A1 (en) * | 2013-03-15 | 2014-09-25 | Purdue Research Foundation | Asthma imaging and therapy |
CN118240918A (zh) | 2013-06-25 | 2024-06-25 | 普罗格诺西斯生物科学公司 | 采用微流控装置的空间编码生物分析 |
EP4374924A2 (de) | 2013-10-18 | 2024-05-29 | Novartis AG | Markierte hemmer des prostataspezifischen membranantigens (psma), ihre verwendung als kontrastmittel und pharmazeutische mittel zur behandlung von prostatakrebs |
AU2014348601A1 (en) * | 2013-11-14 | 2016-05-26 | Endocyte, Inc. | Compounds for positron emission tomography |
EP3865153A1 (de) | 2013-11-19 | 2021-08-18 | Purdue Research Foundation | Patientenauswahlverfahren für entzündungen |
WO2015153345A1 (en) | 2014-04-03 | 2015-10-08 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
WO2015200187A1 (en) * | 2014-06-27 | 2015-12-30 | Reiley Pharmaceuticals, Inc. | Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging |
US20160166679A1 (en) * | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
JP2018504380A (ja) | 2014-12-18 | 2018-02-15 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Reversir(商標)化合物 |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
EP3242688B1 (de) | 2015-01-09 | 2020-01-29 | Reiley Pharmaceuticals, Inc. | Auf cox-2 abzielende, platinhaltige konjugate und deren verwendung bei der behandlung von tumoren und krebs |
EP4119677B1 (de) | 2015-04-10 | 2023-06-28 | Spatial Transcriptomics AB | Räumlich getrennte multiplex-nukleinsäureanalyse von biologischen proben |
CA2989970A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
WO2017030893A1 (en) * | 2015-08-14 | 2017-02-23 | Endocyte, Inc. | Method of imaging with a chelating compound |
ES2926495T3 (es) | 2015-12-04 | 2022-10-26 | 10X Genomics Inc | Métodos y composiciones para el análisis de ácidos nucleicos |
US10857234B2 (en) | 2016-03-16 | 2020-12-08 | Endocyte Inc. | Carbonic anhydrase IX inhibitor conjugates and uses thereof |
JP7027325B2 (ja) | 2016-03-16 | 2022-03-01 | パーデュー・リサーチ・ファウンデイション | 炭酸無水酵素ixを標的とする薬剤および方法 |
US20170296679A1 (en) | 2016-04-18 | 2017-10-19 | Intuitive Surgical Operations, Inc. | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands |
WO2019040474A1 (en) | 2017-08-22 | 2019-02-28 | Purdue Research Foundation | THERAPEUTIC AND RADIOIMAGING CONJUGATES BASED ON FBSA TARGETING POSITIVE CANCERS FOR CARBONIC ANHYDRASE |
MX2020011570A (es) | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Administracion extrahepatica. |
TW202028465A (zh) | 2018-09-28 | 2020-08-01 | 美商阿尼拉製藥公司 | 甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關眼部疾病之使用方法 |
JP2022532652A (ja) | 2019-05-17 | 2022-07-15 | アルニラム ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの経口送達 |
WO2021086982A2 (en) | 2019-10-28 | 2021-05-06 | Beckman Coulter, Inc. | Compounds for the identification of microbial classes and uses thereof |
EP4055165A1 (de) | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon für die behandlung oder prävention ttr-assoziierter augenerkrankungen |
KR20220110749A (ko) | 2019-11-06 | 2022-08-09 | 알닐람 파마슈티칼스 인코포레이티드 | 간외 전달 |
WO2021252499A1 (en) | 2020-06-08 | 2021-12-16 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
US11981960B1 (en) | 2020-07-06 | 2024-05-14 | 10X Genomics, Inc. | Spatial analysis utilizing degradable hydrogels |
US20230257745A1 (en) | 2020-07-10 | 2023-08-17 | Alnylam Pharmaceuticals, Inc. | Circular siRNAs |
CN116916968A (zh) | 2020-10-30 | 2023-10-20 | 托德·斯皮尔 | 基于寡核苷酸的治疗剂及其用途 |
EP4271696A2 (de) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | Oligonukleotid-prodrugs auf basis von mit cyclischem disulfid modifiziertem phosphat |
EP4271695A2 (de) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | Auf 2'-modifiziertem nukleosid basierende oligonukleotid-prodrugs |
WO2022150721A1 (en) * | 2021-01-08 | 2022-07-14 | Lycia Therapeutics, Inc. | Bifunctional folate receptor binding compounds |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2023003922A1 (en) | 2021-07-21 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Metabolic disorder-associated target gene irna compositions and methods of use thereof |
CA3234887A1 (en) | 2021-10-15 | 2023-04-20 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
WO2023220744A2 (en) | 2022-05-13 | 2023-11-16 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
WO2024006999A2 (en) | 2022-06-30 | 2024-01-04 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
WO2024073732A1 (en) | 2022-09-30 | 2024-04-04 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2816110A (en) | 1956-11-23 | 1957-12-10 | Merck & Co Inc | Methods for the production of substituted pteridines |
US5140104A (en) | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
US5175343A (en) * | 1985-01-14 | 1992-12-29 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5242679A (en) * | 1985-01-14 | 1993-09-07 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
NZ217821A (en) | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
EP0273085A1 (de) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen |
US5053493A (en) * | 1987-04-02 | 1991-10-01 | Centocor Cardiovascular Imaging Partners, L.P. | Method for labeling antibodies with a metal ion |
US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
US7238340B1 (en) * | 1991-11-27 | 2007-07-03 | Cis Bio International | Monoamine, diamide, thiol-containing metal chelating agents |
ES2141102T3 (es) * | 1991-02-08 | 2000-03-16 | Diatide Inc | Polipeptidos marcados con tecnecio-99m para la generacion de imagenes. |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US5159079A (en) | 1991-12-20 | 1992-10-27 | Eli Lilly And Company | 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids |
US6022966A (en) | 1993-11-22 | 2000-02-08 | Neorx Corporation | Pretargeting methods and compounds |
DE4311021A1 (de) * | 1993-03-31 | 1994-10-27 | Diagnostikforschung Inst | Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel |
DE4311023C2 (de) * | 1993-03-31 | 1996-05-02 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
DE4311022C2 (de) * | 1993-03-31 | 1996-07-11 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
DE4310999C2 (de) * | 1993-03-31 | 1996-07-18 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ XN¶1¶S¶1¶X' für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
DE4425781A1 (de) * | 1994-07-14 | 1996-01-18 | Schering Ag | Technetium-Sulfonamid-Komplexe, deren Verwendung, diese enthaltende pharmazeutische Mittel, sowie Verfahren zur Herstellung der Komplexe und Mittel |
US6083480A (en) * | 1997-05-01 | 2000-07-04 | Diatide, Inc. | Calcitonin receptor binding reagents |
US6093382A (en) * | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
US6323313B1 (en) * | 1999-06-01 | 2001-11-27 | The University Of Washington | Annexin derivative with endogenous chelation sites |
EP1286704B1 (de) * | 2000-06-02 | 2014-07-23 | Board of Regents, The University of Texas System | ETHYLENEDICYSTEINE (EC)-Glucose Analoge KONJUGATE |
EP1390077B1 (de) | 2001-05-02 | 2014-07-16 | Purdue Research Foundation | Behandlung und diagnose vom makrophagen-vermittelter erkrankung |
EP2258401B1 (de) | 2002-05-06 | 2014-07-09 | Endocyte, Inc. | Folatrezeptor gerichtete bildgebende Konjugate |
EP2529758A3 (de) * | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate |
JP2007526238A (ja) * | 2003-05-06 | 2007-09-13 | パーデュー・リサーチ・ファウンデーション | マクロファージまたは葉酸受容体を標的とする狼瘡治療法 |
-
2003
- 2003-05-06 EP EP10179448.5A patent/EP2258401B1/de not_active Expired - Lifetime
- 2003-05-06 CA CA2484345A patent/CA2484345C/en not_active Expired - Fee Related
- 2003-05-06 EP EP03733967A patent/EP1501551B1/de not_active Expired - Lifetime
- 2003-05-06 ES ES10179448.5T patent/ES2500922T3/es not_active Expired - Lifetime
- 2003-05-06 DK DK10179508.6T patent/DK2260875T3/da active
- 2003-05-06 CN CNB038146835A patent/CN100528241C/zh not_active Expired - Fee Related
- 2003-05-06 ES ES09171503.7T patent/ES2438008T3/es not_active Expired - Lifetime
- 2003-05-06 DK DK09171503.7T patent/DK2151250T3/da active
- 2003-05-06 AU AU2003239383A patent/AU2003239383C1/en not_active Ceased
- 2003-05-06 DE DE60330135T patent/DE60330135D1/de not_active Expired - Lifetime
- 2003-05-06 ES ES10179508.6T patent/ES2472423T3/es not_active Expired - Lifetime
- 2003-05-06 AT AT03733967T patent/ATE448799T1/de not_active IP Right Cessation
- 2003-05-06 EP EP09171503.7A patent/EP2151250B1/de not_active Expired - Lifetime
- 2003-05-06 KR KR1020047017608A patent/KR100978418B1/ko active IP Right Grant
- 2003-05-06 EP EP10179508.6A patent/EP2260875B1/de not_active Expired - Lifetime
- 2003-05-06 DK DK10179448.5T patent/DK2258401T3/da active
- 2003-05-06 WO PCT/US2003/014379 patent/WO2003092742A1/en active Application Filing
- 2003-05-06 PT PT91715037T patent/PT2151250E/pt unknown
- 2003-05-06 US US10/430,519 patent/US7128893B2/en not_active Expired - Lifetime
- 2003-05-06 NZ NZ536467A patent/NZ536467A/en not_active IP Right Cessation
- 2003-05-06 JP JP2004500925A patent/JP4801348B2/ja not_active Expired - Fee Related
- 2003-05-06 CN CN200910151274XA patent/CN101648028B/zh not_active Expired - Fee Related
- 2003-05-06 SI SI200332331T patent/SI2151250T1/sl unknown
- 2003-05-06 SI SI200332355T patent/SI2260875T1/sl unknown
- 2003-05-06 ES ES03733967T patent/ES2336780T3/es not_active Expired - Lifetime
- 2003-05-06 PT PT101795086T patent/PT2260875E/pt unknown
-
2004
- 2004-10-25 IL IL164811A patent/IL164811A/en active IP Right Grant
- 2004-10-26 ZA ZA200408664A patent/ZA200408664B/en unknown
-
2006
- 2006-10-11 US US11/546,099 patent/US7862798B2/en not_active Expired - Fee Related
-
2009
- 2009-09-11 US US12/558,163 patent/US8313728B2/en not_active Expired - Lifetime
-
2010
- 2010-08-16 HK HK10107801.2A patent/HK1141440A1/xx not_active IP Right Cessation
-
2012
- 2012-10-18 US US13/654,527 patent/US8865126B2/en not_active Expired - Fee Related
-
2013
- 2013-03-11 US US13/793,624 patent/US8834842B2/en not_active Expired - Fee Related
- 2013-12-27 CY CY20131101164T patent/CY1114733T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE448799T1 (de) | Folatrezeptor gerichtete bildgebende konjugate | |
LTPA2017036I1 (lt) | Kalicheamicino darinio-nešiklio konjugatai | |
DE60230163D1 (de) | Sicherheitsgurt-vorspannvorrichtung | |
CY1113054T1 (el) | Παραγωγα διαμινης | |
CY1114008T1 (el) | Θειενοπυριμιδινικες ενωσεις και χρηση τους | |
CY1105705T1 (el) | Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6 | |
ATE302775T1 (de) | Carbolinderivate | |
ECSP056167A (es) | Fenil quinolinas y su uso como agentes estrogénicos | |
CY1108738T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου | |
DE60110844D1 (de) | Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten | |
DE60215179D1 (de) | Dolastatin 10 derivate | |
ATE346067T1 (de) | Carbolinderivate | |
DE60237109D1 (de) | Rbesserte transistoreigenschaften | |
BR0307894A (pt) | Heterocìclos tricìclicos fundidos úteis para o tratamento de distúrbios hiperproliferativos | |
BR0312378A (pt) | Moduladores de receptores de cck-1 | |
PA8543701A1 (es) | Fenil-heterociclil-eteres | |
DE502004000410D1 (de) | Gurtstraffer bei einer höhenverstellbaren Gurtumlenkeinrichtung | |
NO20032577D0 (no) | Söm for korrugert belte | |
DE50200900D1 (de) | Fixiereinrichtung | |
DE60215804D1 (de) | 4-aminopyrimidine derivate | |
ATE321760T1 (de) | N-aryl-2-oxazolidinone und deren derivate | |
DE60039695D1 (de) | Antifucoidan antikörper | |
BRPI0409143A (pt) | n-aril-2-oxazolidinona-5-carboxamidas e seus derivados | |
SE0202617L (sv) | Lysande spännbandssträckare | |
DE60317303D1 (de) | Hemoglobin Konjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |